PPARG and Alzheimer disease: PPARγ agonists ameliorate AD-related mitochondrial dysfunction by inhibiting Aβ peptide production, discussed above, by eliciting mitobiogenesis (Strum et al., 2007; Miglio et al., 2009), and improving mitochondrial membrane potential (Wang et al., 2002; Pipatpiboon et al., 2012).